世界の耐性緑膿菌感染症治療薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Resistant Pseudomonas Aeruginosa Infections Drugs Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A14711 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、耐性緑膿菌感染症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。耐性緑膿菌感染症治療薬の種類別市場規模（半合成ペニシリン、セファロスポリン、ラクタム薬、その他）、用途別市場規模（病院、クリニック、在宅ケア）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・耐性緑膿菌感染症治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：ContraFect Corp、Inhibrx LP、Achaogen Inc、LegoChem Biosciences Inc、Melinta Therapeutics Inc、Novartis AG、AmpliPhi Biosciences Corp、Biolytics Pharma、Shionogi & Co Ltd ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：半合成ペニシリン、セファロスポリン、ラクタム薬、その他 ・用途別分析2016年-2026年：病院、クリニック、在宅ケア ・耐性緑膿菌感染症治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・耐性緑膿菌感染症治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・耐性緑膿菌感染症治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・耐性緑膿菌感染症治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・耐性緑膿菌感染症治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Resistant Pseudomonas Aeruginosa Infections Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Resistant Pseudomonas Aeruginosa Infections Drugs size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Resistant Pseudomonas Aeruginosa Infections Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Resistant Pseudomonas Aeruginosa Infections Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Semi-Synthetic Penicillin
Cephalosporin
Lactam Drugs
Others

Market segment by Application can be divided into
Hospital
Clinic
Home Care

The key market players for global Resistant Pseudomonas Aeruginosa Infections Drugs market are listed below:
ContraFect Corp
Inhibrx LP
Achaogen Inc
LegoChem Biosciences Inc
Melinta Therapeutics Inc
Novartis AG
AmpliPhi Biosciences Corp
Biolytics Pharma
Shionogi & Co Ltd

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Resistant Pseudomonas Aeruginosa Infections Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, with price, sales, revenue and global market share of Resistant Pseudomonas Aeruginosa Infections Drugs from 2019 to 2021.
Chapter 3, the Resistant Pseudomonas Aeruginosa Infections Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Resistant Pseudomonas Aeruginosa Infections Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Resistant Pseudomonas Aeruginosa Infections Drugs market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Resistant Pseudomonas Aeruginosa Infections Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Semi-Synthetic Penicillin
1.2.3 Cephalosporin
1.2.4 Lactam Drugs
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home Care
1.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size & Forecast
1.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Value (2016-2026))
1.4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume (2016-2026)
1.4.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity Analysis
1.5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Total Production Capacity (2016-2026)
1.5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Resistant Pseudomonas Aeruginosa Infections Drugs Market Drivers
1.6.2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Restraints
1.6.3 Resistant Pseudomonas Aeruginosa Infections Drugs Trends Analysis
2 Manufacturers Profiles
2.1 ContraFect Corp
2.1.1 ContraFect Corp Details
2.1.2 ContraFect Corp Major Business
2.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
2.1.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Inhibrx LP
2.2.1 Inhibrx LP Details
2.2.2 Inhibrx LP Major Business
2.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
2.2.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Achaogen Inc
2.3.1 Achaogen Inc Details
2.3.2 Achaogen Inc Major Business
2.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
2.3.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 LegoChem Biosciences Inc
2.4.1 LegoChem Biosciences Inc Details
2.4.2 LegoChem Biosciences Inc Major Business
2.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
2.4.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Melinta Therapeutics Inc
2.5.1 Melinta Therapeutics Inc Details
2.5.2 Melinta Therapeutics Inc Major Business
2.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
2.5.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business
2.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
2.6.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 AmpliPhi Biosciences Corp
2.7.1 AmpliPhi Biosciences Corp Details
2.7.2 AmpliPhi Biosciences Corp Major Business
2.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
2.7.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Biolytics Pharma
2.8.1 Biolytics Pharma Details
2.8.2 Biolytics Pharma Major Business
2.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
2.8.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Shionogi & Co Ltd
2.9.1 Shionogi & Co Ltd Details
2.9.2 Shionogi & Co Ltd Major Business
2.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
2.9.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturer
3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Resistant Pseudomonas Aeruginosa Infections Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturer Market Share
3.4.2 Top 6 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturer Market Share
3.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Resistant Pseudomonas Aeruginosa Infections Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Region
4.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2016-2026)
4.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026)
4.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026)
4.4 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026)
4.5 South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026)
4.6 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume by Type (2016-2026)
5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2016-2026)
5.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume by Application (2016-2026)
6.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2016-2026)
6.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2026)
7.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2026)
7.3 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country
7.3.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2026)
8.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2026)
8.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country
8.3.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Region
9.3.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2026)
10.2 South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2026)
10.3 South America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country
10.3.1 South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country
11.3.1 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Resistant Pseudomonas Aeruginosa Infections Drugs Typical Distributors
12.3 Resistant Pseudomonas Aeruginosa Infections Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. ContraFect Corp Basic Information, Manufacturing Base and Competitors
Table 4. ContraFect Corp Major Business
Table 5. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 6. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Inhibrx LP Basic Information, Manufacturing Base and Competitors
Table 8. Inhibrx LP Major Business
Table 9. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 10. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Achaogen Inc Basic Information, Manufacturing Base and Competitors
Table 12. Achaogen Inc Major Business
Table 13. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 14. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. LegoChem Biosciences Inc Basic Information, Manufacturing Base and Competitors
Table 16. LegoChem Biosciences Inc Major Business
Table 17. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 18. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Melinta Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 20. Melinta Therapeutics Inc Major Business
Table 21. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 22. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 24. Novartis AG Major Business
Table 25. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 26. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. AmpliPhi Biosciences Corp Basic Information, Manufacturing Base and Competitors
Table 28. AmpliPhi Biosciences Corp Major Business
Table 29. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 30. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Biolytics Pharma Basic Information, Manufacturing Base and Competitors
Table 32. Biolytics Pharma Major Business
Table 33. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 34. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Shionogi & Co Ltd Basic Information, Manufacturing Base and Competitors
Table 36. Shionogi & Co Ltd Major Business
Table 37. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product and Services
Table 38. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 40. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 41. Market Position of Manufacturers in Resistant Pseudomonas Aeruginosa Infections Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 42. Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 43. Head Office and Resistant Pseudomonas Aeruginosa Infections Drugs Production Site of Key Manufacturer
Table 44. Resistant Pseudomonas Aeruginosa Infections Drugs New Entrant and Capacity Expansion Plans
Table 45. Resistant Pseudomonas Aeruginosa Infections Drugs Mergers & Acquisitions in the Past Five Years
Table 46. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2016-2021e) & (K Pcs)
Table 47. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021-2026) & (K Pcs)
Table 48. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 49. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2021-2026) & (USD Million)
Table 50. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 51. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Pcs)
Table 52. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 53. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2021-2026) & (USD Million)
Table 54. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2016-2021e) & (USD/Pcs)
Table 55. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2021-2026) & (USD/Pcs)
Table 56. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 57. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Pcs)
Table 58. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 59. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2021-2026) & (USD Million)
Table 60. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2016-2021e) & (USD/Pcs)
Table 61. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2021-2026) & (USD/Pcs)
Table 62. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2016-2021e) & (K Pcs)
Table 63. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Pcs)
Table 64. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 65. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2021-2026) & (USD Million)
Table 66. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 67. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Pcs)
Table 68. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 69. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Pcs)
Table 70. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2016-2021e) & (K Pcs)
Table 71. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Pcs)
Table 72. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 73. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2021-2026) & (USD Million)
Table 74. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 75. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Pcs)
Table 76. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 77. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Pcs)
Table 78. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2016-2021e) & (K Pcs)
Table 79. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2021-2026) & (K Pcs)
Table 80. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 81. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2021-2026) & (USD Million)
Table 82. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 83. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Pcs)
Table 84. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 85. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Pcs)
Table 86. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2016-2021e) & (K Pcs)
Table 87. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Pcs)
Table 88. South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 89. South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2021-2026) & (USD Million)
Table 90. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 91. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Pcs)
Table 92. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 93. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Pcs)
Table 94. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2016-2021e) & (K Pcs)
Table 95. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2021-2026) & (K Pcs)
Table 96. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 97. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2021-2026) & (USD Million)
Table 98. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2016-2021e) & (K Pcs)
Table 99. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2021-2026) & (K Pcs)
Table 100. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2016-2021e) & (K Pcs)
Table 101. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2021-2026) & (K Pcs)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. Resistant Pseudomonas Aeruginosa Infections Drugs Typical Distributors
Table 105. Resistant Pseudomonas Aeruginosa Infections Drugs Typical Customers
List of Figures
Figure 1. Resistant Pseudomonas Aeruginosa Infections Drugs Picture
Figure 2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type in 2020
Figure 3. Semi-Synthetic Penicillin
Figure 4. Cephalosporin
Figure 5. Lactam Drugs
Figure 6. Others
Figure 7. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application in 2020
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Home Care
Figure 11. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 12. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (2016-2026) & (K Pcs)
Figure 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2016-2026) & (USD/Pcs)
Figure 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity (2016-2026) & (K Pcs)
Figure 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 17. Resistant Pseudomonas Aeruginosa Infections Drugs Market Drivers
Figure 18. Resistant Pseudomonas Aeruginosa Infections Drugs Market Restraints
Figure 19. Resistant Pseudomonas Aeruginosa Infections Drugs Market Trends
Figure 20. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturer in 2020
Figure 21. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Manufacturer in 2020
Figure 22. Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 23. Top 3 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturer (Revenue) Market Share in 2020
Figure 24. Top 6 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturer (Revenue) Market Share in 2020
Figure 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2016-2026)
Figure 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2016-2026)
Figure 27. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026) & (USD Million)
Figure 28. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026) & (USD Million)
Figure 29. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026) & (USD Million)
Figure 30. South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026) & (USD Million)
Figure 31. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (2016-2026) & (USD Million)
Figure 32. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2016-2026)
Figure 33. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2016-2026)
Figure 34. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2016-2026) & (USD/Pcs)
Figure 35. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2016-2026)
Figure 36. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2016-2026)
Figure 37. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2016-2026) & (USD/Pcs)
Figure 38. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2016-2026)
Figure 39. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2016-2026)
Figure 40. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2016-2026)
Figure 41. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2016-2026)
Figure 42. United States Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2016-2026)
Figure 46. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2016-2026)
Figure 47. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2016-2026)
Figure 48. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2016-2026)
Figure 49. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2016-2026)
Figure 58. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Korea Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2016-2026)
Figure 65. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2016-2026)
Figure 66. South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2016-2026)
Figure 67. South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2016-2026)
Figure 71. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2016-2026)
Figure 72. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. South Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source

---